79456-30-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-3-bromo-5-(trifluoromethyl)-pyridine is used as a building block for the synthesis of biologically active compounds. The trifluoromethyl group enhances the lipophilicity and metabolic stability of these compounds, making it a valuable intermediate for the preparation of medicinal products.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Amino-3-bromo-5-(trifluoromethyl)-pyridine serves as a key intermediate for the synthesis of bioactive compounds with potential applications in crop protection and pest control.
Used in Material Science:
2-Amino-3-bromo-5-(trifluoromethyl)-pyridine is utilized in the development of new materials due to its unique chemical properties, which can contribute to the creation of innovative materials with specific characteristics.
Used as a Reagent in Organic Synthesis:
2-Amino-3-bromo-5-(trifluoromethyl)-pyridine also functions as a reagent in organic synthesis, facilitating various chemical reactions and contributing to the synthesis of complex organic molecules.

InChI:InChI=1/C6H4BrF3N2/c7-4-1-3(6(8,9)10)2-12-5(4)11/h1-2H,(H2,11,12)

Upstream product

• 79456-29-4 3,6-dichloro-5-(trifluoromethyl)pyridin-2-amine 
• 74784-70-6 2-amino-5-trifluoromethylpyridine 
• 13534-99-1 2-Amino-3-bromopyridine 
• 887144-94-7 Togni's reagent II 

Downstream Products

• 202409-73-2 2-amino-3-[4-(methylthio)phenyl]-5-trifluoromethyl-pyridine 
• 1065607-74-0 3-phenoxy-5-(trifluoromethyl)pyridin-2-amine 
• 1228376-74-6 8-bromo-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid 
• 1254309-00-6 8-bromo-N-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide 
• 107867-51-6 5-(trifluoromethyl)-2,3-pyridinediamine 
• 1211514-97-4 2-amino-3-cyano-5-trifluoromethylpyridine 
• 847985-20-0 3-(phenylethynyl)-5-(trifluoromethyl)pyridin-2-amine 
• 71701-92-3 2-chloro-3-bromo-5-(trifluoromethyl)pyridine 

Relevant academic research and scientific papers

Transition metal-free direct C–H trifluoromethyltion of (hetero)arenes with Togni's reagent

A new transition-metal-free direct C–H trifluoromethylation reaction of (hetero)arenes with Togni's reagent was developed. This transformation proceeded smoothly under mild conditions and exhibited good tolerance of many synthetically relevant functional groups. It provided an alternative approach for the synthesis of trifluoromethylated (hetero)arenes.

HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES

Provided herein are Heterocyclic compounds of formula (I): and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.

PEST CONTROL COMPOSITION FOR HARMFUL ARTHROPODS, AND PEST CONTROL METHOD FOR HARMFUL ARTHROPODS

A harmful arthropod control composition comprising a compound represented by the following Formula (1) wherein each symbol represents definitions described in the specification, and one or more fungicidal compounds, which are selected from among azoles, s

2-AMINOPYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).

2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2

The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).

2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors

A series of novel 2-alkoxy, 2-thioalkoxy and 2-amino-3-(4- methylsulfonyl)phenylpyridines has been synthesized and shown to be highly potent and selective cyclooxygenase-2 (COX-2) inhibitors. Structure-activity relationship studies have demonstrated that central pyridine ring substituents play an important role in the COX-2 potency, selectivity vs the COX-1 enzyme, and oral activity.

Substituted pyridines as selective cyclooxygenase-2 inhibitors

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

2-aminopyridines as inhibitors of cyclooxygenase-2

The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

2-pyridinyl-3(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors

A series of novel 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines has been synthesized and evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1, and COX-2. Optimum COX-2 activity is observed by introduction of a substituent at C5 of the central pyridine. 5- Chloro-3-(4-methylsulfonyl)phenyl-2(2-methyl-5-pyridinyl)pyridine 33 was identified as the optimum compound in this series.